Allergy Impact Factor

The journal's rank matters as much as the headline number. A 12.0 JIF in a narrow, high-quality specialty lane means something different from a 12.0 at a broad multidisciplinary venue.

Here, the signal is reinforced by the JCI of 2.11. The journal is performing well above category average after normalization, which matters in allergy and immunology because citation behavior differs a lot across subfields.

The smaller but still useful detail is that the two-year JIF is slightly higher than the five-year JIF. That usually means the recent citation cycle has been especially strong. In Allergy, that makes sense. The field has been moving fast around endotypes, biologics, severe asthma, atopic dermatitis, food allergy, and immunotherapy.

The JCR row above is the authoritative impact factor on this page. For the longer directional view, the table below uses the open Scopus-based impact score series as a trend proxy.

Directionally, the open citation signal is up from 6.86 in 2023 to 7.54 in 2024. More importantly, the journal has stayed strong across a full decade rather than relying on one extraordinary spike.

That is what you want to see in a specialty clinical journal. The number is high because the journal remains central to a real field, not because of one temporary attention cycle.

The common mistake is to see a top-ranked allergy journal and assume any high-quality immunology paper is worth the shot.

That is usually wrong. Allergy is still a readership-specific journal. The paper generally needs to matter for:

• allergic disease mechanisms
• asthma or airway inflammation with real allergy relevance
• biomarker or endotype work that changes interpretation or management
• immunotherapy, biologics, or clinically meaningful translational allergy science

If allergic disease is just the setting rather than the scientific center, the fit weakens fast.

In our pre-submission review work on manuscripts targeting Allergy, the main misses are usually not formatting mistakes. They are fit mistakes. The science may be real, but the manuscript is still written like a general immunology paper with allergy terminology layered on top.

Editors at this journal usually screen for whether the work changes how allergy specialists think, diagnose, stratify, or treat.

In our pre-submission review work on manuscripts targeting Allergy, four failure patterns recur.

The manuscript is immunology-first and allergy-second. The pathway work may be sound, but the allergic-disease consequence is too thin for the journal's readership.

Clinical phenotype definition is weak. Biomarker and cohort papers often fail because the disease classification, comparator groups, or outcome framing are not strong enough to support the clinical claim.

The translational bridge is missing. Mechanistic animal or cell work can be interesting and still fail if there is no believable path to patient meaning.

The paper describes associations without changing decisions. This shows up in asthma, food allergy, and dermatitis studies where the results are statistically clean but clinically inert.

If that sounds familiar, an Allergy submission readiness check is often more valuable than another abstract rewrite.

The impact factor does not tell you whether the journal will treat your endpoint, phenotype definition, or translational bridge as clinically meaningful enough. Allergy is still a field journal with strong editorial taste. Papers that are technically sound but vague about patient relevance often underperform at first decision.

That is why the metric is most useful as a placement tool, not a submission excuse. It tells you the journal matters. It does not tell you your manuscript speaks the language of allergy specialists strongly enough to belong there.

It also does not tell you whether the paper feels current enough for a fast-moving biologics and endotype field.